Serum Levels of Soluble CD23, but not Soluble CD25, Predict Disease Progression in Early Stage B-Cell Chronic Lymphocytic Leukemia

Serum levels of the soluble forms of CD23 (sCD23) and CD25 (sCD25) were prospectively analyzed with respect to their prognostic relevance in early stage B-cell chronic lymphocytic leukemia (B-CLL). SCD23 and sCD25 levels were determined in 105 patients with newly diagnosed B-CLL (Binet stage A). In...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia & lymphoma 1997-11, Vol.27 (5-6), p.523-532
Hauptverfasser: Knauf, W. U., Langenmayer, I., Ehlers, B., Mohr, B., Adorf, D., Nerl, C. H., Hallek, M., Zwingers, T. H., Emmerich, B., Thiel, E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 532
container_issue 5-6
container_start_page 523
container_title Leukemia & lymphoma
container_volume 27
creator Knauf, W. U.
Langenmayer, I.
Ehlers, B.
Mohr, B.
Adorf, D.
Nerl, C. H.
Hallek, M.
Zwingers, T. H.
Emmerich, B.
Thiel, E.
description Serum levels of the soluble forms of CD23 (sCD23) and CD25 (sCD25) were prospectively analyzed with respect to their prognostic relevance in early stage B-cell chronic lymphocytic leukemia (B-CLL). SCD23 and sCD25 levels were determined in 105 patients with newly diagnosed B-CLL (Binet stage A). In 93 of the patients, these levels were correlated with other already established indicators for risk of disease progression, including the histologic pattern of bone marrow infiltration, lymphocyte doubling time (LDT), and the serum level of thymidine kinase (TK). High serum levels of both sCD23 and of sCD25 were associated with a diffuse bone marrow infiltration, a LDT ≤12 months, and elevated (>5 U/L) serum TK, respectively. Moreover, examination of the clinical course of 76 untreated patients showed that high levels of sCD23, but not of sCD25, at initial diagnosis were linked with disease progression. Furthermore, in a stepwise Cox regression model, high levels of sCD23 and a short LDT were shown to be strong predictors of progressive disease within the first year of disease presentation. Therefore, it appears to be justified to incorporate sCD23 levels into the risk profile of early stage B-CLL and to take them into account for stratification in risk-adapted treatment strategies.
doi_str_mv 10.3109/10428199709058320
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_9477135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17187295</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-c1356c466997209bca57253a035917eb74cfda2a4286778f0443ed51612acd693</originalsourceid><addsrcrecordid>eNqFUU1v1DAQtRCotIUfwAHJJ04N-DNeCy6Qlg9pJZAWzpHjTLouTry1HVCu_PJ6tSsEQsBpZjzvPT3PQ-gJJc85JfoFJYKtqNaKaCJXnJF76JQSpismCL-_7wWrCkA8RGcp3RBCpK7ZCTrRQinK5Sn6sYE4j3gN38AnHAa8CX7uPODmkvEL3M0ZTyH_-iov8KcIvbMZX7oEJkGZw3WElFyYsJvwlYl-wZtsrgG_qRrwHjfbGCZn8XoZd9tgl7zvYf4KozOP0IPB-ASPj_UcfXl79bl5X60_vvvQvF5XVnCWK1v81lbUdfkuI7qzRiomuSFcaqqgU8IOvWGmXKRWajUQITj0ktaUGdvXmp-jZwfdXQy3M6Tcji7Z4s5MEObUKi2lVLz-L5AqulJMywKkB6CNIaUIQ7uLbjRxaSlp9wG1fwRUOE-P4nM3Qv-TcUyk7F8d9m4aQhzN9xB932az-BCHaCbr0l767_Ivf6Nvwfi8tSZCexPmOJUD_8PcHc81rjo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17187295</pqid></control><display><type>article</type><title>Serum Levels of Soluble CD23, but not Soluble CD25, Predict Disease Progression in Early Stage B-Cell Chronic Lymphocytic Leukemia</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Access via Taylor &amp; Francis</source><creator>Knauf, W. U. ; Langenmayer, I. ; Ehlers, B. ; Mohr, B. ; Adorf, D. ; Nerl, C. H. ; Hallek, M. ; Zwingers, T. H. ; Emmerich, B. ; Thiel, E.</creator><creatorcontrib>Knauf, W. U. ; Langenmayer, I. ; Ehlers, B. ; Mohr, B. ; Adorf, D. ; Nerl, C. H. ; Hallek, M. ; Zwingers, T. H. ; Emmerich, B. ; Thiel, E.</creatorcontrib><description>Serum levels of the soluble forms of CD23 (sCD23) and CD25 (sCD25) were prospectively analyzed with respect to their prognostic relevance in early stage B-cell chronic lymphocytic leukemia (B-CLL). SCD23 and sCD25 levels were determined in 105 patients with newly diagnosed B-CLL (Binet stage A). In 93 of the patients, these levels were correlated with other already established indicators for risk of disease progression, including the histologic pattern of bone marrow infiltration, lymphocyte doubling time (LDT), and the serum level of thymidine kinase (TK). High serum levels of both sCD23 and of sCD25 were associated with a diffuse bone marrow infiltration, a LDT ≤12 months, and elevated (&gt;5 U/L) serum TK, respectively. Moreover, examination of the clinical course of 76 untreated patients showed that high levels of sCD23, but not of sCD25, at initial diagnosis were linked with disease progression. Furthermore, in a stepwise Cox regression model, high levels of sCD23 and a short LDT were shown to be strong predictors of progressive disease within the first year of disease presentation. Therefore, it appears to be justified to incorporate sCD23 levels into the risk profile of early stage B-CLL and to take them into account for stratification in risk-adapted treatment strategies.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.3109/10428199709058320</identifier><identifier>PMID: 9477135</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>Biomarkers, Tumor - blood ; Bone Marrow - physiology ; Chronic lymphocytic leukemia ; Disease Progression ; early stage ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - blood ; Leukemia, Lymphocytic, Chronic, B-Cell - etiology ; Leukemia, Lymphocytic, Chronic, B-Cell - immunology ; Neoplasm Staging ; Receptors, IgE - blood ; Receptors, Interleukin-2 - blood ; Risk Factors ; soluble CD23 ; Statistics as Topic ; Thymidine Kinase - blood</subject><ispartof>Leukemia &amp; lymphoma, 1997-11, Vol.27 (5-6), p.523-532</ispartof><rights>1997 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-c1356c466997209bca57253a035917eb74cfda2a4286778f0443ed51612acd693</citedby><cites>FETCH-LOGICAL-c432t-c1356c466997209bca57253a035917eb74cfda2a4286778f0443ed51612acd693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/10428199709058320$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/10428199709058320$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9477135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knauf, W. U.</creatorcontrib><creatorcontrib>Langenmayer, I.</creatorcontrib><creatorcontrib>Ehlers, B.</creatorcontrib><creatorcontrib>Mohr, B.</creatorcontrib><creatorcontrib>Adorf, D.</creatorcontrib><creatorcontrib>Nerl, C. H.</creatorcontrib><creatorcontrib>Hallek, M.</creatorcontrib><creatorcontrib>Zwingers, T. H.</creatorcontrib><creatorcontrib>Emmerich, B.</creatorcontrib><creatorcontrib>Thiel, E.</creatorcontrib><title>Serum Levels of Soluble CD23, but not Soluble CD25, Predict Disease Progression in Early Stage B-Cell Chronic Lymphocytic Leukemia</title><title>Leukemia &amp; lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>Serum levels of the soluble forms of CD23 (sCD23) and CD25 (sCD25) were prospectively analyzed with respect to their prognostic relevance in early stage B-cell chronic lymphocytic leukemia (B-CLL). SCD23 and sCD25 levels were determined in 105 patients with newly diagnosed B-CLL (Binet stage A). In 93 of the patients, these levels were correlated with other already established indicators for risk of disease progression, including the histologic pattern of bone marrow infiltration, lymphocyte doubling time (LDT), and the serum level of thymidine kinase (TK). High serum levels of both sCD23 and of sCD25 were associated with a diffuse bone marrow infiltration, a LDT ≤12 months, and elevated (&gt;5 U/L) serum TK, respectively. Moreover, examination of the clinical course of 76 untreated patients showed that high levels of sCD23, but not of sCD25, at initial diagnosis were linked with disease progression. Furthermore, in a stepwise Cox regression model, high levels of sCD23 and a short LDT were shown to be strong predictors of progressive disease within the first year of disease presentation. Therefore, it appears to be justified to incorporate sCD23 levels into the risk profile of early stage B-CLL and to take them into account for stratification in risk-adapted treatment strategies.</description><subject>Biomarkers, Tumor - blood</subject><subject>Bone Marrow - physiology</subject><subject>Chronic lymphocytic leukemia</subject><subject>Disease Progression</subject><subject>early stage</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - blood</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - etiology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</subject><subject>Neoplasm Staging</subject><subject>Receptors, IgE - blood</subject><subject>Receptors, Interleukin-2 - blood</subject><subject>Risk Factors</subject><subject>soluble CD23</subject><subject>Statistics as Topic</subject><subject>Thymidine Kinase - blood</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU1v1DAQtRCotIUfwAHJJ04N-DNeCy6Qlg9pJZAWzpHjTLouTry1HVCu_PJ6tSsEQsBpZjzvPT3PQ-gJJc85JfoFJYKtqNaKaCJXnJF76JQSpismCL-_7wWrCkA8RGcp3RBCpK7ZCTrRQinK5Sn6sYE4j3gN38AnHAa8CX7uPODmkvEL3M0ZTyH_-iov8KcIvbMZX7oEJkGZw3WElFyYsJvwlYl-wZtsrgG_qRrwHjfbGCZn8XoZd9tgl7zvYf4KozOP0IPB-ASPj_UcfXl79bl5X60_vvvQvF5XVnCWK1v81lbUdfkuI7qzRiomuSFcaqqgU8IOvWGmXKRWajUQITj0ktaUGdvXmp-jZwfdXQy3M6Tcji7Z4s5MEObUKi2lVLz-L5AqulJMywKkB6CNIaUIQ7uLbjRxaSlp9wG1fwRUOE-P4nM3Qv-TcUyk7F8d9m4aQhzN9xB932az-BCHaCbr0l767_Ivf6Nvwfi8tSZCexPmOJUD_8PcHc81rjo</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>Knauf, W. U.</creator><creator>Langenmayer, I.</creator><creator>Ehlers, B.</creator><creator>Mohr, B.</creator><creator>Adorf, D.</creator><creator>Nerl, C. H.</creator><creator>Hallek, M.</creator><creator>Zwingers, T. H.</creator><creator>Emmerich, B.</creator><creator>Thiel, E.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19971101</creationdate><title>Serum Levels of Soluble CD23, but not Soluble CD25, Predict Disease Progression in Early Stage B-Cell Chronic Lymphocytic Leukemia</title><author>Knauf, W. U. ; Langenmayer, I. ; Ehlers, B. ; Mohr, B. ; Adorf, D. ; Nerl, C. H. ; Hallek, M. ; Zwingers, T. H. ; Emmerich, B. ; Thiel, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-c1356c466997209bca57253a035917eb74cfda2a4286778f0443ed51612acd693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biomarkers, Tumor - blood</topic><topic>Bone Marrow - physiology</topic><topic>Chronic lymphocytic leukemia</topic><topic>Disease Progression</topic><topic>early stage</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - blood</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - etiology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</topic><topic>Neoplasm Staging</topic><topic>Receptors, IgE - blood</topic><topic>Receptors, Interleukin-2 - blood</topic><topic>Risk Factors</topic><topic>soluble CD23</topic><topic>Statistics as Topic</topic><topic>Thymidine Kinase - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knauf, W. U.</creatorcontrib><creatorcontrib>Langenmayer, I.</creatorcontrib><creatorcontrib>Ehlers, B.</creatorcontrib><creatorcontrib>Mohr, B.</creatorcontrib><creatorcontrib>Adorf, D.</creatorcontrib><creatorcontrib>Nerl, C. H.</creatorcontrib><creatorcontrib>Hallek, M.</creatorcontrib><creatorcontrib>Zwingers, T. H.</creatorcontrib><creatorcontrib>Emmerich, B.</creatorcontrib><creatorcontrib>Thiel, E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia &amp; lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knauf, W. U.</au><au>Langenmayer, I.</au><au>Ehlers, B.</au><au>Mohr, B.</au><au>Adorf, D.</au><au>Nerl, C. H.</au><au>Hallek, M.</au><au>Zwingers, T. H.</au><au>Emmerich, B.</au><au>Thiel, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Levels of Soluble CD23, but not Soluble CD25, Predict Disease Progression in Early Stage B-Cell Chronic Lymphocytic Leukemia</atitle><jtitle>Leukemia &amp; lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>27</volume><issue>5-6</issue><spage>523</spage><epage>532</epage><pages>523-532</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>Serum levels of the soluble forms of CD23 (sCD23) and CD25 (sCD25) were prospectively analyzed with respect to their prognostic relevance in early stage B-cell chronic lymphocytic leukemia (B-CLL). SCD23 and sCD25 levels were determined in 105 patients with newly diagnosed B-CLL (Binet stage A). In 93 of the patients, these levels were correlated with other already established indicators for risk of disease progression, including the histologic pattern of bone marrow infiltration, lymphocyte doubling time (LDT), and the serum level of thymidine kinase (TK). High serum levels of both sCD23 and of sCD25 were associated with a diffuse bone marrow infiltration, a LDT ≤12 months, and elevated (&gt;5 U/L) serum TK, respectively. Moreover, examination of the clinical course of 76 untreated patients showed that high levels of sCD23, but not of sCD25, at initial diagnosis were linked with disease progression. Furthermore, in a stepwise Cox regression model, high levels of sCD23 and a short LDT were shown to be strong predictors of progressive disease within the first year of disease presentation. Therefore, it appears to be justified to incorporate sCD23 levels into the risk profile of early stage B-CLL and to take them into account for stratification in risk-adapted treatment strategies.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>9477135</pmid><doi>10.3109/10428199709058320</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1042-8194
ispartof Leukemia & lymphoma, 1997-11, Vol.27 (5-6), p.523-532
issn 1042-8194
1029-2403
language eng
recordid cdi_pubmed_primary_9477135
source MEDLINE; Taylor & Francis Medical Library - CRKN; Access via Taylor & Francis
subjects Biomarkers, Tumor - blood
Bone Marrow - physiology
Chronic lymphocytic leukemia
Disease Progression
early stage
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - blood
Leukemia, Lymphocytic, Chronic, B-Cell - etiology
Leukemia, Lymphocytic, Chronic, B-Cell - immunology
Neoplasm Staging
Receptors, IgE - blood
Receptors, Interleukin-2 - blood
Risk Factors
soluble CD23
Statistics as Topic
Thymidine Kinase - blood
title Serum Levels of Soluble CD23, but not Soluble CD25, Predict Disease Progression in Early Stage B-Cell Chronic Lymphocytic Leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A47%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Levels%20of%20Soluble%20CD23,%20but%20not%20Soluble%20CD25,%20Predict%20Disease%20Progression%20in%20Early%20Stage%20B-Cell%20Chronic%20Lymphocytic%20Leukemia&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Knauf,%20W.%20U.&rft.date=1997-11-01&rft.volume=27&rft.issue=5-6&rft.spage=523&rft.epage=532&rft.pages=523-532&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.3109/10428199709058320&rft_dat=%3Cproquest_pubme%3E17187295%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17187295&rft_id=info:pmid/9477135&rfr_iscdi=true